University of Minnesota. Driven to Discover.
Scientists are seeing high rates of treatment failure as they struggle to eliminate the disease in the region.
A total of 62.4% of patients taking tafenoquine were free of P vivax after 6 months.
Earlier this week, a leading expert voiced similar concerns, noting that the WHO hadn't made its voice heard.
Group discusses the narrow window now open for tackling artemisinin resistance.
The tests could be used for detection and to help in drug development.
Get CIDRAP news and other free newsletters.
Sign up now»
Unrestricted financial support provided by
Grant support for ASP provided by
Become an underwriter»
CIDRAP - Center for Infectious Disease Research and PolicyOffice of the Vice President for Research, University of Minnesota, Minneapolis, MN
© 2019 Regents of the University of Minnesota. All rights reserved.The University of Minnesota is an equal opportunity educator and employer.